Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- JAN Determined for 8 Drug Candidate Compounds
November 29, 2011
- Record 101 Generics from 30 Companies Listed for Aricept
November 29, 2011
- MHLW Says Sept Drug Price Settlement Rate Dips to 78.1%, Falling Below 2009 Level
November 28, 2011
- MHLW Issues Notification on Modifications of Approval for Iressa
November 28, 2011
- CSIMC to Discuss Additional Price Cuts for Long-Listed Drugs
November 28, 2011
- DPJ's Subcommittee for PAL Amendment Begins Deliberations Nov. 28, to Compile Opinion by End-Jan
November 25, 2011
- Obligatory Use of Generics for Welfare Recipients to Be Discussed: Policy Screening
November 25, 2011
- HPB, HSB Issue Notification to Ensure Stable Supplies of Flu Drugs This Season
November 25, 2011
- Experts Call For Establishment of Independent Vaccine Policy Organization
November 25, 2011
- Otsuka to Challenge Grand Champion Santen in Market for Dry Eye Treatments
November 25, 2011
- Policy Screening Committee Proposes Major Cutbacks in Long-Listed Drug Prices, Additional Decreases Possible
November 24, 2011
- Patients’ Copayments for OTC-like Drugs to Be Increased on a Trial Basis: Policy Screening
November 24, 2011
- Council Approves New 10-Year Strategy for Hepatitis Research
November 24, 2011
- MHLW Council Approves Subsidizing Telaprevir Combination Therapy
November 24, 2011
- DPJ WT to Propose New Measures to Promote Generics
November 24, 2011
- Committee on OTC Drugs Recommends SSP’s Vaginal Candidiasis Treatment for Approval
November 24, 2011
- Korosho Issues Notification to Ensure Stable Supplies of Flu Drugs This Season
November 24, 2011
- Korosho’s Council Approves Subsidizing 3-Drug Combination Therapy Including Teraprevir
November 22, 2011
- MHLW Study Group Postpones Decision on Relief System for Victims of Health Damages Due to Anticancer Drugs
November 21, 2011
- After Delay, CSIMC Recommends Listing of Ilaris for Treatment of CAPS
November 21, 2011
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…